Who’s the patient? Ethics in and around material-fetal surgery
PhD ceremony: Ms. M.L. Misarela Loureiro Rodrigues, 16.15 uur, Academiegebouw, Broerstraat 5, Groningen
Dissertation: Who’s the patient? Ethics in and around material-fetal surgery
Promotor(s): prof. P.P. van den Berg, prof. M. Düwell
Faculty: Medical Sciences
Maternal-Fetal surgery (MFS) consists of a series of surgical techniques which aim at correcting or improving the outcome of life-threatening or severely debilitating congenital birth defects, such as congenital diaphragmatic hernia and myelomeningocele. Today, most of MFS remains investigational, as its safety and efficacy are still to be proven. For some indications and for a small number of patients, MFS has however become the standard of care. In either case, although the fetus is the surgery’s immediate or potential beneficiary, in order to operate on it, surgeons must inevitably pass through the woman’s abdomen, uterus, and membranes, causing harms to her health that she would not endure were she to continue her pregnancy to term without MFS, were she to terminate that pregnancy, or were she to be pregnant with a ‘healthy’ fetus. This undeniable and apparently innocuous fact, is however the source of many “headaches” for pregnant women, physicians, moral philosophers, ethicists and lawyers. The different chapters of this thesis deal with some of the causes of those “headaches”, namely, 1) What is owed, morally, to those involved in MFS (women and fetuses)? 2) How should the ethical review of MFS research protocols (namely, randomized controlled trials (RCT)) proceed, on which basis, and according to which criteria should they be ethically sanctioned? 3) How much weight should be given to patient/research subject’s preferences in the design and conduct of MFS RCT? 4) Under which conditions can Dutch patients be referred for MFS for myelomeningocele? 5) How should the counseling of prospective candidates proceed?
Last modified: | 13 March 2020 01.00 a.m. |
More news
-
16 December 2024
Jouke de Vries: ‘The University will have to be flexible’
2024 was a festive year for the University of Groningen. Jouke de Vries, the chair of the Executive Board, looks back.
-
27 August 2024
UMCG gaat onderzoeksfaciliteiten beschikbaar stellen voor geneesmiddelenontwikkeling
Om de beschikbaarheid en effectiviteit van geneesmiddelen in Nederland te verbeteren gaat het UMCG het bedrijf G² Solutions opzetten. Dit bedrijf moet ervoor gaan zorgen dat belangrijke technologische ontwikkelingen op het gebied van DNA sequencing...
-
17 July 2024
Veni-grants for ten researchers
The Dutch Research Council (NWO) has awarded a Veni grant of up to €320,000 each to ten researchers of the University of Groningen and the UMCG. The Veni grants are designed for outstanding researchers who have recently gained a PhD.